Turning Point ROS1/TRK Inhibitor Repotrectinib Could Stand Out On Durability

 
• By Alaric DeArment
  
Turning Point's repotrectinib showed a high level of durability of response • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category